146 related articles for article (PubMed ID: 32704044)
1. Targeting the PLK1-FOXO1 pathway as a novel therapeutic approach for treating advanced prostate cancer.
Gheghiani L; Shang S; Fu Z
Sci Rep; 2020 Jul; 10(1):12327. PubMed ID: 32704044
[TBL] [Abstract][Full Text] [Related]
2. The function of FOXO1 in the late phases of the cell cycle is suppressed by PLK1-mediated phosphorylation.
Yuan C; Wang L; Zhou L; Fu Z
Cell Cycle; 2014; 13(5):807-19. PubMed ID: 24407358
[TBL] [Abstract][Full Text] [Related]
3. Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2/xL in HER2-positive breast cancer.
Saatci Ö; Borgoni S; Akbulut Ö; Durmuş S; Raza U; Eyüpoğlu E; Alkan C; Akyol A; Kütük Ö; Wiemann S; Şahin Ö
Oncogene; 2018 Apr; 37(17):2251-2269. PubMed ID: 29391599
[TBL] [Abstract][Full Text] [Related]
4. Eribulin synergizes with Polo-like kinase 1 inhibitors to induce apoptosis in rhabdomyosarcoma.
Stehle A; Hugle M; Fulda S
Cancer Lett; 2015 Aug; 365(1):37-46. PubMed ID: 25917079
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of polo-like kinase 1 (Plk1) enhances the antineoplastic activity of metformin in prostate cancer.
Shao C; Ahmad N; Hodges K; Kuang S; Ratliff T; Liu X
J Biol Chem; 2015 Jan; 290(4):2024-33. PubMed ID: 25505174
[TBL] [Abstract][Full Text] [Related]
6. Silencing of polo-like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer.
Reagan-Shaw S; Ahmad N
FASEB J; 2005 Apr; 19(6):611-3. PubMed ID: 15661849
[TBL] [Abstract][Full Text] [Related]
7. [Chinese medicinal compound CFF-1 induces the apoptosis and cycle-arrest of prostate cancer cells via the PI3K/AKT/FOXO1 signaling pathway].
Zhang Y; Wu ZM; Lei BH; Lu ZJ; Zhu QY; Xu FS; Zhang MS; Liu P
Zhonghua Nan Ke Xue; 2017 Sep; 23(9):828-837. PubMed ID: 29726666
[TBL] [Abstract][Full Text] [Related]
8. Preferential Killing of Tetraploid Colon Cancer Cells by Targeting the Mitotic Kinase PLK1.
Jemaà M; Kifagi C; Serrano SS; Massoumi R
Cell Physiol Biochem; 2020 Apr; 54(2):303-320. PubMed ID: 32259417
[TBL] [Abstract][Full Text] [Related]
9. PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy.
Tan J; Li Z; Lee PL; Guan P; Aau MY; Lee ST; Feng M; Lim CZ; Lee EY; Wee ZN; Lim YC; Karuturi RK; Yu Q
Cancer Discov; 2013 Oct; 3(10):1156-71. PubMed ID: 23887393
[TBL] [Abstract][Full Text] [Related]
10. Plk1-dependent microtubule dynamics promotes androgen receptor signaling in prostate cancer.
Hou X; Li Z; Huang W; Li J; Staiger C; Kuang S; Ratliff T; Liu X
Prostate; 2013 Sep; 73(12):1352-63. PubMed ID: 23661607
[TBL] [Abstract][Full Text] [Related]
11. Cotargeting Polo-Like Kinase 1 and the Wnt/β-Catenin Signaling Pathway in Castration-Resistant Prostate Cancer.
Li J; Karki A; Hodges KB; Ahmad N; Zoubeidi A; Strebhardt K; Ratliff TL; Konieczny SF; Liu X
Mol Cell Biol; 2015 Dec; 35(24):4185-98. PubMed ID: 26438599
[TBL] [Abstract][Full Text] [Related]
12. Co-Targeting Plk1 and DNMT3a in Advanced Prostate Cancer.
Zhang Z; Cheng L; Zhang Q; Kong Y; He D; Li K; Rea M; Wang J; Wang R; Liu J; Li Z; Yuan C; Liu E; Fondufe-Mittendorf YN; Li L; Han T; Wang C; Liu X
Adv Sci (Weinh); 2021 Jul; 8(13):e2101458. PubMed ID: 34051063
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of cyclin-dependent kinase phosphorylation of FOXO1 and prostate cancer cell growth by a peptide derived from FOXO1.
Lu H; Liu P; Pan Y; Huang H
Neoplasia; 2011 Sep; 13(9):854-63. PubMed ID: 21969818
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Plk1 represses androgen signaling pathway in castration-resistant prostate cancer.
Zhang Z; Chen L; Wang H; Ahmad N; Liu X
Cell Cycle; 2015; 14(13):2142-8. PubMed ID: 25927139
[TBL] [Abstract][Full Text] [Related]
15. Polo-like kinase 1-mediated phosphorylation of Forkhead box protein M1b antagonizes its SUMOylation and facilitates its mitotic function.
Zhang J; Yuan C; Wu J; Elsayed Z; Fu Z
J Biol Chem; 2015 Feb; 290(6):3708-19. PubMed ID: 25533473
[TBL] [Abstract][Full Text] [Related]
16. Phosphorylation of Plk1 at S137 and T210 is inhibited in response to DNA damage.
Tsvetkov L; Stern DF
Cell Cycle; 2005 Jan; 4(1):166-71. PubMed ID: 15611664
[TBL] [Abstract][Full Text] [Related]
17. Differential Cellular Effects of Plk1 Inhibitors Targeting the ATP-binding Domain or Polo-box Domain.
Shin SB; Woo SU; Yim H
J Cell Physiol; 2015 Dec; 230(12):3057-67. PubMed ID: 25975351
[TBL] [Abstract][Full Text] [Related]
18. Designed inhibitor for nuclear localization signal of polo-like kinase 1 induces mitotic arrest.
Chen F; Zhuo X; Qin T; Guo X; Zhang C; Lai L
Chem Biol Drug Des; 2017 May; 89(5):732-740. PubMed ID: 27882722
[TBL] [Abstract][Full Text] [Related]
19. Activation of FOXO1 by Cdk1 in cycling cells and postmitotic neurons.
Yuan Z; Becker EB; Merlo P; Yamada T; DiBacco S; Konishi Y; Schaefer EM; Bonni A
Science; 2008 Mar; 319(5870):1665-8. PubMed ID: 18356527
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological inhibition of Polo-like kinase 1 (PLK1) by BI-2536 decreases the viability and survival of hamartin and tuberin deficient cells via induction of apoptosis and attenuation of autophagy.
Valianou M; Cox AM; Pichette B; Hartley S; Paladhi UR; Astrinidis A
Cell Cycle; 2015; 14(3):399-407. PubMed ID: 25565629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
